ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
129.125,51
1,74%
S&P 500
5.969,34
0,35%
US Dollar vs BRL
5,801
0,00%
Bitcoin
96.367,87
-1,45%
Brent Oil
74,65
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Astria Therapeutics Inc (ATXS)

  7. Astria Therapeutics Inc (ATXS) Notícias

ATXS

Astria Therapeutics (ATXS)

Astria Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ATXS
DataHoraFonteTítuloCódigoCompanhia
14/11/202419:45Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ATXSAstria Therapeutics Inc
14/11/202414:03Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ATXSAstria Therapeutics Inc
13/11/202418:10Business WireAstria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:ATXSAstria Therapeutics Inc
13/11/202418:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATXSAstria Therapeutics Inc
13/11/202410:00Business WireAstria Therapeutics to Present at Upcoming Jefferies London Healthcare ConferenceNASDAQ:ATXSAstria Therapeutics Inc
04/11/202418:10Business WireAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATXSAstria Therapeutics Inc
30/10/202409:00Business WireAstria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific MeetingNASDAQ:ATXSAstria Therapeutics Inc
21/10/202409:00Business WireAstria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific MeetingNASDAQ:ATXSAstria Therapeutics Inc
16/10/202409:00Business WireEuropean Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary AngioedemaNASDAQ:ATXSAstria Therapeutics Inc
30/09/202409:00Business WireAstria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary AngioedemaNASDAQ:ATXSAstria Therapeutics Inc
27/09/202409:00Business WireAstria Therapeutics to Present at Upcoming Global Angioedema ForumNASDAQ:ATXSAstria Therapeutics Inc
19/09/202409:00Business WireAstria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology CongressNASDAQ:ATXSAstria Therapeutics Inc
30/08/202409:00Business WireAstria Therapeutics to Present at Upcoming Bradykinin SymposiumNASDAQ:ATXSAstria Therapeutics Inc
29/08/202409:00Business WireAstria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:ATXSAstria Therapeutics Inc
12/08/202417:56Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ATXSAstria Therapeutics Inc
12/08/202417:10Business WireAstria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:ATXSAstria Therapeutics Inc
12/08/202417:00Business WireAstria Therapeutics Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary AngioedemaNASDAQ:ATXSAstria Therapeutics Inc
07/08/202409:00Business WireAstria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare ConferenceNASDAQ:ATXSAstria Therapeutics Inc
06/06/202417:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATXSAstria Therapeutics Inc
06/06/202417:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATXSAstria Therapeutics Inc
30/05/202409:00Business WireAstria Therapeutics to Present at Upcoming Jefferies Healthcare ConferenceNASDAQ:ATXSAstria Therapeutics Inc
24/05/202409:00Business WireAstria Therapeutics to Present at Upcoming Eastern Allergy ConferenceNASDAQ:ATXSAstria Therapeutics Inc
23/05/202409:00Business WireAstria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology CongressNASDAQ:ATXSAstria Therapeutics Inc
09/05/202417:10Business WireAstria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:ATXSAstria Therapeutics Inc
08/05/202409:00Business WireAstria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual MeetingNASDAQ:ATXSAstria Therapeutics Inc
09/04/202409:00Business WireAstria Therapeutics Appoints Sunil Agarwal to Its Board of DirectorsNASDAQ:ATXSAstria Therapeutics Inc
25/03/202408:30Business WireAstria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAENASDAQ:ATXSAstria Therapeutics Inc
04/03/202419:20Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATXSAstria Therapeutics Inc
04/03/202418:10Business WireAstria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateNASDAQ:ATXSAstria Therapeutics Inc
04/03/202418:02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ATXSAstria Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ATXS

Seu Histórico Recente

BIT
PMALPF
Etf
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados